Federated Hermes’s Palvella Therapeutics PVLA Stock Holding History

Federated Hermes’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$66.2M	Hold	433,015	–	–	0.1%	234
2026 Q1	$54M	Buy	433,015 +64,977	+18%	+$6.78M	0.09%	242
2025 Q4	$38.5M	Buy	368,038 +28,991	+9%	+$2.47M	0.06%	313
2025 Q3	$21.3M	Buy	+339,047	New	+$15.1M	0.04%	414
2020 Q1	–	Hold	0	–	-$1K	–	2373
2019 Q4	–	Sell	-404	Closed	-$112K	–	2156
2019 Q3	$110K	Buy	+404	New	+$156K	﹤0.01%	1652
2018 Q3	–	Sell	-9	Closed	-$4K	–	2336
2018 Q2	$4K	Sell	9 -25	-74%	-$11.9K	﹤0.01%	2049
2018 Q1	$19K	Sell	34 -1	-3%	-$619	﹤0.01%	1775
2017 Q4	$21K	Buy	+35	New	+$16.3K	﹤0.01%	1764
2017 Q3	–	Sell	-7	Closed	-$3K	–	2203
2017 Q2	$3K	Buy	+7	New	+$2.05K	﹤0.01%	2018

Other funds holding PVLA

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Federated Hermes's PVLA Position: Q2 2026 in Review

Federated Hermes held its Palvella Therapeutics (PVLA) position steady in Q2 2026 at 433,015 shares worth $66.2M. The position accounts for 0.1% of the portfolio, ranked #234.

Federated Hermes first reported a position in PVLA in Q2 2017 and has held it in 9 quarters since. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

Federated Hermes held 433,015 shares of Palvella Therapeutics worth $66.2M as of Q2 2026.
Federated Hermes left its Palvella Therapeutics share count unchanged in Q2 2026.
Palvella Therapeutics made up 0.1% of Federated Hermes's portfolio in Q2 2026, its #234 holding.
Federated Hermes first reported a position in Palvella Therapeutics in Q2 2017 and has held it in 9 quarters since.
197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.